Entering text into the input field will update the search result below

Theravance Biopharma Q4 results mixed, co to reduce headcount by about 17%

Feb. 27, 2023 4:24 PM ETTheravance Biopharma, Inc. (TBPH)By: Anuron Mitra, SA News Editor
  • Theravance Biopharma press release (NASDAQ:TBPH): Q4 GAAP EPS of -$0.15 beats by $0.02.
  • Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M.
  • Discontinuing investments in research, reducing headcount by approximately 17%.
  • Increases capital return program to $325 million from $250 million; as of Feb. 27, approximately $170 million remains in the program.
  • Commits to declassify the board of directors.
  • Reaffirms expectation that co will generate non-GAAP profit in 2H 2023.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About TBPH

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Theravance Biopharma, Inc.
AN2 Therapeutics, Inc.
Wave Life Sciences Ltd.
Evolus, Inc.
Tarsus Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.